How to Do Due Diligence on a Veterinary Practice Buyer in 2026

Key takeaways

• Reverse due diligence is what sellers do to buyers — researching the acquirer’s financial capacity, track record, PE sponsor, integration model, and deal-term risk before signing anything.
• Most sellers skip it entirely, which is why offers that look strong on paper sometimes deliver less than expected once the integration begins and the earnout triggers are tested.
• The PE sponsor behind a buyer matters as much as the buyer itself. The sponsor controls the capital, the timeline, and the priorities that drive post-sale behavior — including how earnouts are administered.
• Call references the buyer did NOT give you. Buyers curate positive references. The owners you find from the buyer’s acquisition list, not the pre-approved list, give you the unfiltered picture.
• A competitive process is the most effective due-diligence tool available. Multiple offers on the same timeline let you compare integration promises, earnout design, and holdback terms side by side — context that a single direct offer never gives you.

There is a conversation I have heard more than once over dinner with a vet who is already past closing. They sold.

The headline number looked right. But somewhere between the letter of intent and month six of the transition, things started feeling different from what they had been told.

The integration moved faster than promised. The earnout targets turned out to be harder to hit than they looked on paper.

Staff left. The vet felt trapped by the non-compete while watching the practice they’d built for 20 years run in a direction they couldn’t control.

None of that is inevitable. And almost none of it is unforeseeable.

The information that would have changed the outcome was available before the LOI was signed — if the seller had known to ask for it.

That is what due diligence on a veterinary practice buyer means in practice. Most people know due diligence as what buyers do to sellers: financial audits, chart reviews, staff interviews, operational checklists.

Fewer sellers know that the process runs in both directions, and that the questions they should be asking before they sign are just as important as anything on the buyer’s checklist.

This article walks you through what reverse due diligence looks like in a 2026 veterinary practice sale — what to research, what to ask, and how to interpret the answers.

What does due diligence on a veterinary practice buyer actually mean in 2026?

Reverse due diligence is the process a seller uses to research and evaluate a buyer before agreeing to a transaction. It covers the buyer’s financial capacity to close, their PE sponsor and fund timeline, their track record with prior sellers, their integration approach, and the risk-shifting terms embedded in the offer structure.

Most sellers do far less of this than buyers do. A buyer will spend 60 to 90 days and several hundred thousand dollars running your numbers through their accountants.

Many sellers spend less than a week thinking critically about the entity they are about to hand their life’s work to — and whether that entity will do what it says it will.

The asymmetry is understandable. Selling a practice is emotional and exhausting, and by the time a letter of intent arrives, sellers are often relieved just to have an offer.

But the work of vetting the buyer is not optional if you want the outcome to match the promise.

How to check a veterinary buyer’s financial capacity before signing

The most basic buyer question is whether they can actually close. A buyer without confirmed financing is a buyer who can take your practice off the market for months, then walk away. You need to know, before you sign, where the money is coming from and how certain it is.

For PE-backed consolidators, this usually means asking: Is the acquisition capital from an existing committed fund, or does the buyer need to raise additional capital for this specific deal? Most major platforms — NVA (backed by JAB Holdings), PetVet Care Centers (backed by Ares Management), AmeriVet (backed by AEA Investors and ADIA), Mission Pet Health (backed by Shore Capital and Silver Lake) — operate with committed capital from institutional sponsors.

Asking for documentation of that commitment is not unusual or aggressive; it is standard in any well-run sale process.

For smaller or newer buyers, this question is even more critical. An individual veterinarian buyer typically needs bank financing.

Ask early whether they have a pre-approval letter or lender commitment, and what conditions remain on the financing.

The question you are really asking is: what is the probability this deal actually closes once we sign? A buyer who can provide documentation of committed financing is categorically lower-risk than one who cannot. That risk difference matters when you are about to take your practice off the market.

Why does the PE sponsor behind a buyer matter so much to a seller?

The PE sponsor controls the capital, the exit timeline, and the priorities that drive the buyer’s behavior after closing. Understanding who the sponsor is — and where that sponsor’s fund is in its life cycle — tells you more about your post-sale life than any integration promise.

Here is the dynamic that most sellers are not told about. PE funds typically have a defined life: most target a 4-to-7-year hold period before selling or recapitalizing the platform.

A hold period is simply the length of time a sponsor expects to own the platform before its next liquidity event — the sale, recapitalization, or IPO.

A sponsor in year two of a fresh fund has runway to be patient. A sponsor in year six of a five-year fund has investors who expect a return, which creates pressure to maximize margins and speed up an exit.

That pressure can translate into faster cost cuts, harder earnout administration, and slower capital investment in the practices they own — all of which affect your day-to-day experience as a seller who is staying on post-closing.

I ask about this on behalf of every seller I work with. Not because any particular sponsor’s posture is bad, but because it is genuinely relevant information for understanding what the next 3 to 5 years looks like inside that platform.

The Today’s Veterinary Business “Great Compression” year-end 2025 review noted that PE groups that bought practices in 2021, 2022, and 2023 are now approaching their recap windows — which can prompt ownership changes as early investors look to exit. A seller who rolls over equity into one of those platforms needs to understand that timeline clearly before signing.

See our deeper look at how PE structures affect deal outcomes in how private equity pays for veterinary practices.

How to check a buyer’s track record with prior sellers

Ask the buyer for a list of practices they have acquired in the past 2 to 3 years in markets similar to yours. That list is the raw material for the most valuable due diligence work you will do.

Once you have the list, use it to find sellers who are NOT on the buyer’s recommended reference list. Buyers curate positive references.

The owners they suggest you call were selected because the call will go well. The owners you find independently — by calling a practice from the acquisition list that the buyer did not mention — give you the unedited version of post-closing life inside that platform.

The questions to ask those owners are open-ended, not yes-or-no. Ask:

• “Did the integration happen at the pace and in the way the buyer described before you signed?”
• “How did the earnout targets hold up once the buyer’s team was running operations?”
• “What changed with staff in the first 90 days that you did not expect?”
• “If you were doing it again, would you sell to the same buyer or run a wider process?”

The specific answers matter less than the pattern across multiple calls. If 3 of 5 sellers you reach say the earnout triggers were redefined in a way that made them harder to hit once the buyer had operational control, that is a pattern worth taking seriously before you sign an agreement with an earnout in it.

At Transitions Elite, we run this reference work as a standard part of the Elite Selling System — vetting each buyer the way a doorman with a velvet rope vets who gets inside, so every bidder at the table is one we have actually researched, not just one who made a phone call. When a seller is evaluating a specific buyer’s offer inside a competitive process, we have often already spoken to prior sellers at that platform, which is context a seller approaching that buyer directly would never have.

What integration questions should I ask a veterinary practice buyer?

Get specific about what changes on day one versus what changes over time. Integration promises are easy to make; the details of how they actually execute determine whether your staff stays, your clients stay, and the earnout targets you signed up for are achievable.

Ask the buyer directly:

• Which back-office systems move to the buyer’s platform immediately — HR, payroll, scheduling, pharmacy ordering?
• Will staff be absorbed into the buyer’s benefits plan, and will compensation change in year one?
• Will the practice name change, and if so, on what timeline?
• Who is the integration lead who will be on-site, and what authority does the selling vet retain in the first year?
• How are clinical protocols handled — do you mandate specific formulary choices or remain clinically neutral?

A well-prepared buyer answers these questions with specifics. A buyer who defaults to “we take a light-touch approach” without supporting detail is giving you a positioning statement, not a plan.

Written commitments in the purchase agreement are more durable than verbal ones. If a buyer tells you your practice name will not change for at least 3 years, ask for that language in the agreement. If a buyer says your medical director role will be preserved for the full earnout period, ask for that in writing.

The only integration promises that bind the buyer legally are the ones that make it into the documents.

We cover the mechanics of how deal structure terms affect your take-home price in our article on veterinary practice earnouts and rollover equity. Read that alongside this article if you are evaluating an offer with a rollover or earnout component.

What risk-shifting deal terms should sellers scrutinize in 2026?

Every term in a PE-backed offer that is not a straight cash payment at closing represents some degree of risk being transferred from the buyer to you. That is not inherently bad — it is how deal structures work across all industries. But understanding which terms shift risk, and how much, is essential before you accept a headline number.

The main risk-shifting terms in 2026 veterinary practice deals:

Term	What it means	Key questions to ask
Earnout	Part of the price paid after closing, contingent on hitting performance targets	What exactly triggers the earnout — revenue, EBITDA, patient count? Who controls the post-sale operations that drive those metrics?
Rollover equity	Keeping a slice of ownership in the new platform instead of all-cash at close	When can you liquidate it? What triggers liquidity — the sponsor’s exit, a recapitalization, a specific date?
Holdback	A portion of price retained by the buyer post-closing, not placed with any third party	How long is the retention period — 12 months, 24 months? What triggers a claim against it, and what is the dispute process?
Non-compete	Agreement not to practice veterinary medicine in a defined area for a defined period	What is the radius, and what does it actually prevent you from doing in the geography you live in?

None of these terms are deal-breakers by default. Each is standard in PE-backed acquisitions, and each reflects the buyer’s reasonable need to protect the investment they are making.

The work is in the details: how the earnout EBITDA is calculated (and whether post-closing management fees or overhead allocations are deducted before the calculation), how long rollover equity is locked and what triggers its release, how large the holdback is relative to the total price, and how broad the non-compete radius is in practice.

Capstone Partners‘ April 2026 Pet Sector M&A Update noted that deal momentum in the Vet & Health segment has picked up after a softer 2025, with buyer appetite rebounding — which means sellers in 2026 are not negotiating from weakness. A well-prepared seller with multiple offers on the table has the leverage to push back on the terms above and get them modified.

A seller who accepted a direct offer in isolation has no leverage at all.

For more on what to expect in the overall sale process, our sell my veterinary practice guide covers the full arc from preparation through closing.

Does antitrust and regulatory status matter when vetting a buyer?

Yes — and it is a question most sellers forget to ask. Several of the largest veterinary consolidators have faced Federal Trade Commission review during prior acquisitions, and some operate under ongoing prior-approval or prior-notice orders.

JAB Holdings, the sponsor behind NVA, operates under an FTC prior-notice requirement — described by the FTC as “the first of its kind in a Commission order” — that requires JAB to provide advance notice before completing additional veterinary acquisitions. This does not prevent the acquisition, but it adds a regulatory step that can extend the time between signing an LOI and closing.

For a seller who is counting on a specific closing date for tax planning or practice transition purposes, this timeline matters.

Similarly, the FTC required JAB to divest clinics as conditions of both the NVA acquisition and the subsequent SAGE Veterinary Partners acquisition. The regulatory scrutiny reflects the FTC’s concern about concentration in local veterinary markets, not the quality of the buyer — but a seller in a market where concentration is already high should understand whether the buyer’s regulatory posture introduces closing risk.

The practical question to ask: Has your platform or your sponsor faced any FTC, DOJ, or state antitrust review in the past five years, and are there any prior-approval or prior-notice requirements currently in effect? A well-prepared buyer will answer this transparently. An evasive answer is itself data.

For an overview of the consolidator landscape and which platforms are currently active, see our veterinary practice consolidators directory.

How does a competitive process support due diligence on a veterinary practice buyer?

A competitive process is the most powerful due-diligence tool a seller has — because it generates a comparison set. When 4 to 6 buyers submit structured offers on the same timeline, you can read integration promises, earnout designs, rollover terms, and non-compete scopes side by side. That comparison is what reveals whether what you are being offered is market-standard or a buyer-favorable outlier.

A single direct offer, by contrast, arrives in a vacuum. You have one data point, no context, and a buyer who knows it.

The offer might be the best available — or it might be 2 additional multiples of EBITDA below where a competitive process would land. You cannot know from a sample size of one.

I have walked sellers through this comparison enough times that I stop calling it anecdotal and start calling it a pattern. The practices that run a structured process consistently clear prices that would have been unavailable from any single buyer, not because the competitive process magically inflates value, but because it creates the conditions where every buyer puts their best offer on the table instead of their opening offer.

There is a second, subtler benefit. A competitive process surfaces how buyers behave under pressure — which is the closest proxy available for how they will behave post-closing.

A buyer who responds professionally, moves quickly, provides detailed answers to diligence questions, and doesn’t try to retrade terms at the last moment is demonstrating the same discipline they will likely bring to integration. A buyer who is evasive, slow, or who tries to chip terms in the final days of a process is showing you something about their operating culture before you have signed anything.

If you are evaluating multiple buyers and want to understand who the right fit is for your specific practice, a structured competitive process is the mechanism that gives you the answer.

What is the right time to start due diligence on a buyer?

Before you sign the letter of intent. The LOI is the moment when the buyer gains exclusive negotiating rights and you take your practice off the market. Once exclusivity is in place, your leverage to walk away drops sharply.

The diligence you do after signing the LOI is confirmatory — verifying what you agreed to. The diligence you do before signing is the diligence that actually changes what you agree to.

The reference calls, the sponsor research, the integration questions, the regulatory history check — all of this belongs in the window between receiving the offer and signing the LOI. That window is typically short in a competitive process: buyers will push for a quick decision to lock in exclusivity.

A well-run process builds in the time for sellers to do this work before committing to any one buyer.

The practical implication is to start your buyer research before offers arrive. Know which consolidators are active in your market, understand their sponsors and fund backgrounds, and identify prior sellers at each platform before you are in the middle of evaluating an offer with a deadline attached.

Our practice valuation guide covers the financial preparation that makes you a more informed seller. Buyer research is the complement on the other side of the table.

---

Get a Free Practice Value Estimate →

I work with sellers specifically to build the context they need before they sign anything. That includes running the competitive process, conducting buyer research, and helping sellers understand what the terms they are reading actually mean for their take-home price and their post-sale life.

The way we structure our work at Transitions Elite is success-based — we only get paid when a deal closes, and only out of the value created above what you would have received on your own. That alignment means our incentive is always the same as yours: get you the right buyer, at the best terms, through a process you understand every step of.

---

Frequently asked questions

What is due diligence on a veterinary practice buyer?

Due diligence on a veterinary practice buyer — sometimes called reverse due diligence — is the process a seller uses to research and evaluate a buyer before agreeing to a transaction. It covers the buyer’s financial capacity to close, their PE sponsor and fund timeline, their track record with prior acquisitions, their integration approach, and the risk-shifting terms embedded in the offer structure.

Most sellers do far less of this than buyers do, which is one reason offers that look strong on paper sometimes deliver less than expected.

What questions should I ask a veterinary practice buyer before signing?

Ask buyers: How is this acquisition funded, and can you provide commitment documentation? Which PE sponsor backs you, and where is the fund in its life cycle?

Can you share a list of practices you have acquired in the past three years, with contact names? What changes on day one versus over 90 days?

Which systems — HR, payroll, scheduling, pharmacy — move to your platform immediately? What are the earnout triggers, rollover lockup conditions, and holdback release terms?

Has your sponsor or platform faced any FTC or antitrust review? These 7 questions surface the information most sellers never ask for.

How do I check a veterinary buyer’s track record?

Ask the buyer for a list of their recent practice acquisitions, then contact prior owners yourself — not only those the buyer offers as references. Ask those owners open-ended questions: Did the integration go as described?

Were earnout targets fair, given how post-sale operations changed? Did staff stay?

Would you do the deal again? Buyers curate the references they hand you.

The owners you find on your own give you the unfiltered version.

Why does the PE sponsor behind a buyer matter to a seller?

The PE sponsor controls the acquisition capital and the exit timeline. A sponsor in year six of a five-year fund may be under pressure to cut costs and maximize exit valuation — which can affect staffing, capital investment, and how earnout targets are administered.

A sponsor that just raised a fresh fund has more runway to operate patiently. Understanding which sponsor backs the buyer, and where that fund is in its life cycle, tells you more about what post-closing life looks like than any integration promise.

What are the key risk-shifting deal terms to scrutinize in 2026?

In 2026, the terms most commonly used to shift risk from buyer to seller include earnouts tied to post-sale EBITDA or revenue targets, rollover equity locked until the platform’s next exit or recapitalization, holdbacks retained by the buyer for 12 to 24 months to cover indemnification claims, and non-competes that run several years across a defined geographic radius. None of these are inherently unfair — each reflects legitimate buyer risk management — but their specific design determines how much of your headline number you actually receive and when.

How does running a competitive process help with buyer due diligence?

A competitive process puts multiple qualified buyers in the same room, which gives you a comparison set. When 4 to 6 buyers submit structured offers on the same timeline, you can directly compare integration promises, earnout design, rollover terms, and non-compete scope side by side.

A single direct offer gives you one data point with no context. Competition gives you the context to know whether the terms you are reading are market-standard or buyer-favorable outliers.

Should I ask a buyer about FTC or antitrust issues?

Yes. Some of the largest veterinary PE platforms have operated under FTC prior-approval or prior-notice orders that require regulatory review before completing additional acquisitions.

For a seller, this means a potential delay between signing and closing while the buyer navigates regulatory requirements. Knowing this upfront lets you plan your timeline accordingly, and lets your attorney review whether the specific deal structure triggers any reporting obligations.

What is a holdback in a veterinary practice sale?

A holdback is a portion of the sale price that the buyer retains after closing — not placed with a third party — for a defined period, typically 12 to 24 months, to cover any indemnification claims that arise from the seller’s representations and warranties. If no claims are made, the holdback is released to the seller at the end of the period.

The buyer holds the funds directly; they are not placed in any third-party account.

---

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. Today’s Veterinary Business. “The Great Compression, Year 3.” December 2025. todaysveterinarybusiness.com
3. Evergreen for Founders. “The Rise of Mission Pet Health: What the Southern Vet Merger Means for Independent Practice Owners.” 2025. blog.evergreenforfounders.com
4. GlobeNewswire. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” July 21, 2025. globenewswire.com
5. PrivSource. “Tyree & D’Angelo Partners Launch Continuation Fund for Western Veterinary Partners.” privsource.com

Veterinary practice operations and profession data

6. AVMA. “NVA Splits Into Two Businesses, May Go Public in Next Few Years.” avma.org
7. AAHA. “Corporate Consolidation and the Rise of Private Equity.” Trends Magazine. aaha.org
8. Frontiers in Veterinary Science. “Making the Case for a Resurgent U.S. Independent Veterinary Practice Segment: A SWOT Analysis.” 2025. frontiersin.org

Legal, regulatory, and M&A advisory analysis

9. Federal Trade Commission. “FTC Takes Second Action Against JAB Consumer Partners to Protect Pet Owners from Private Equity Firm’s Rollup of Veterinary Services Clinics.” June 2022. ftc.gov
10. Whiteford, Taylor & Preston LLP. “Private Company M&A — Reverse Diligence: Questions Sellers Should Ask of Bidders.” whitefordlaw.com
11. Paul Hastings LLP. “Considerations for Private Equity After FTC Vet Clinic Deal.” paulhastings.com

Public company disclosures and PE filings

12. BusinessWire. “AmeriVet Veterinary Partners Acquired by AEA Investors LP and ADIA from Imperial Capital.” March 2022. businesswire.com
13. JAB Holding Company. “Press Release: Ares Management Agrees to Sell NVA, the Leading Veterinary Care Platform, to JAB Holding Company.” jabholco.com
14. Private Equity Wire. “KKR to Acquire PetVet Care Centers.” privateequitywire.co.uk